The evidence linking prostaglandins (PGs), particularly of the E series, to human mammary cancer is substantial, and this topic has been reviewed previously (Bennett, 1979; Karmali, 1980) . In this disease excess prostaglandin E production by tumours appears to be responsible for occasional cases of hypercalcaemia (Seyberth et al., 1975) and may contribute to the development of metastatic disease (Rolland et al., 1980) . The survival time after mastectomy was found to correlate inversely with amounts of "prostaglandinlike" material extracted from human mammary cancers . The ever-increasing list of references presenting evidence of enhanced PG content and synthetic capacity in many human tumours of different types therefore makes the reasons for continuing to study PGs in cancer compelling.
Recent studies suggest that the many physiological and pathological effects formerly attributed to the classical PGs, namely, PGE2 and PGF2a, may in fact be attributable to the action of other oxygenated metabolites of arachidonic acid, including thromboxanes, prostacyclin and other potentially important prostanoids.
We report here a comparison of tissue content and biosynthesis of PGE1, PGE2, PGF2a, 6-keto-PGF15, (a stable degradation product of PGI2) and TXB2 (a stable degradation product of thromboxane A2) in a series of 24 human mammary carcinomas. PG and TXB2 production in each specimen was examined in relation to tumour size, axillary lymph node metastases, distant metastasis and hormone status (oestrogen and progesterone).
Materials and methods
The study concerns Analytical methods-Extraction The procedure for extracting the prostaglandins was described earlier (Karmali et al., 1982) . Briefly, a trace of [3H]-PG was added to aliquots of standards and samples before being extracted once with 3.5ml petroleum ether. After acidification to pH 3.5, the samples were extracted twice with diethyl ether, dried under nitrogen and reconstituted in assay buffer. The efficiency of the extraction procedure to this point was 85-95%.
Radioimmunoassay (RIA) Standard quantities of each prostaglandin (0-10OOpg) or the extracted sample to be measured were prepared in 0.1 ml aliquots of assay buffer. Antiserum and label were added successively in 0.1 ml aliquots and incubated at 4°C for 8-12h. Bound and free [3H]-PG were separated by 0.5ml dextran-coated charcoal (0.5-1.0% by wt) to estimate the amount of each compound in the unknown samples. The sensitivity of the assays has been found to be -10 pg. The intra-assay coefficient of variation was 9.0%.
Assay of prostaglandin-like material extracted from mammary tissue Solid tumour fragments weighing between 0.5 and 1 g were ground using a mortar and pestle at 2°C in a 1:5 (g:ml) tissue:buffer volume of MES buffer (1 M 2n-morpholino-ethane sulphonic acid, pH 7.4, containing 2mM CaC12, 2% glycerol and 1 mM monothio-glycerol). No antioxidant was added to avoid altering the PG synthetase. Homogenates were centrifuged at 800g for 15min at 4°C. Each supernatant thus obtained was further spun at 150,000 g for 1 h at 4°C and stored in duplicate at -20°C. After adding [3H]-PGE2 as a tracer, the PGs were extracted and measured by RIA as described above. Such measurements represent the yield of the 5 immunoreactive compounds in noncancerous and tumour tissues. The remaining microsomal pellet obtained after centrifugation at 150,000g was saved for prostaglandin synthetase studies.
Prostaglandin synthetase assay The microsomal pellet was suspended in MES buffer; its protein content was measured by the Lowry method and adjusted to 0.5mg protein ml-' in MES buffer. Biosynthesis of PGs by microsomal preparations of noncancerous and neoplastic mammary tissue was assayed by a modification of the procedure described by Rolland et al. (1980) . A 0.2ml aliquot of the microsomal fraction was incubated at 37°C with 0.8 ml MES buffer containing 1.25mM reduced glutathione, 1.25mM adrenaline, and 1.25 MM sodium arachidonate.
After incubation for 10min, [3H]-PGE2 was added as a tracer to evaluate procedural losses. PGs were extracted with a petroleum ether/diethyl ether mixture as described earlier (Karmali et al., 1982 Tumour and noncancerous tissue PG yields correlated significantly with each other (P<0.001). Noncancerous tissue yields were thus used as controls to obtain "adjusted" values upon which the rest of the analysis was based.
The methodology has been tested carefully in our laboratory using mouse, rat and human mammary carcinomas to evaluate if PG production results during the processing of the material. Although this evaluation has involved processing of a large number of tumour specimens, data are presented for PG yield in 5 replicates of only one such tumour specimen processed at 2°C as described using MES buffer with or without ibuprofen (20 Mg ml-1). The following are mean values (ng g-1 wet tissue) for control followed by samples processed in the presence of ibuprofen, both at 2°C: (Table III) . (Flower, 1974; Flower & Vane, 1974) . Tumour and noncancerous tissue PG production in vitro correlated with each other: PGE1 (P < 0.001), PGE2 (P < 0.001), 6-keto-PGFia (P < 0.001) and TXB2 (P <0.001). Noncancerous tissue PG yields were thus used as controls to obtain "adjusted" values upon which the rest of the statistical analysis is based.
PG synthetase activity: Tumour size The only significant relationship between tumour size and adjusted PG production by microsomal PG synthetase was with TXB2 (P=0.04) (Table VI) . PG synthetase activity: Proportion of positive axillary lymph nodes The only significant correlation between the proportion of positive nodes and adjusted production by microsomal enzyme was with TXB2 (P=0.015) (Table VI) . PG synthetase activity: Distant metastases (to liver, bone and lung) Seven lesions had detected positive distant metastases in the 24 patients studied. None of the adjusted tumour PG production yields were significantly different in patients with metastases compared with those not associated with detected metastases (Table VII) . (Bennett et al., 1975 (Bennett et al., , 1977 "Tumour PGE2 production (tumour-noncancerous tissue) was higher in progesterone +ve receptor breast lesions.
cTumour TXB2 production (tumour-noncancerous tissue) was higher in progesterone -ve receptor breast lesions. different precursor, dihomo-gamma-lino-lenate (C20: 3), whereas the rest of the metabolites examined are from arachidonate, and this fatty acid was the only prostaglandin precursor added to the reaction mixture. Tests of cross-reactivity with PGE1 antisera ruled out the possibility that PGE2 was being measured instead of PGE,.
The reason for the observed elevation in yields of immunoreactive PG-like material in breast cancer tissue is not clearly understood. Several proposed possibilities include: (1) increased enzyme synthetic activity; (2) decreased catabolic activity; (3) increased availability of precursor polyenoic acids; (4) a breakdown in the negative feedback controls which normally regulate PG formation (Horrobin, 1980) .
In an attempt to evaluate the importance of each of the 5 PG moieties individually, we have analysed the relationships between tissue yields and PG production by microsomal PG synthetase with clinical variables such as tumour size, proportion of positive axillary lymph nodes, distant metastases (to liver, bone and lung), oestrogen receptor content, progesterone receptor content and Stage of breast malignancy. TXB2 was the only arachidonate metabolite showing a significant relationship with tumour size and the number of positive nodes.
However, tissue production of 6-keto-PGF1,, tended to be less in breast tumours associated with a higher number of positive nodes. Rolland et al. (1980) concluded from a study of 91 breast leasions that PGE2 production by microsomal PG synthetase may be used as a marker of high metastatic potential for neoplastic cells in breast cancer. Bennett et al. (1975 Bennett et al. ( , 1977 found that bone metastases were associated with tumours having high levels of PG-like material. Analysis without adjusting our PGE2 results for the normal tissue values gives results consistent with these reports. In addition, we have adjusted our findings by subtracting the amount from the normal paired sample. Such an approach takes into consideration any variations due either to processing or to differences between individual specimens.
Several variables complicate the interpretation of PG studies in breast cancer masses. Mechanical disruption-a necessity in analysing PGs in solid tumours-can stimulate PG production but since ibuprofen did not alter the yield, it seems that disruption at 2°C does not stimulate PG synthesis by tumour tissue. Presumably normal tissues would not synthesise PGs with this method. Tissues are not homogenous and lymphocytes and monocytes are present to varying extents. They probably contribute to the PG yield but their numbers do not correlate to the amount of PG (Bennett et al., 1977; Rolland et al., 1980) . PG production and metabolism may vary between individuals in a way unrelated to the neoplastic lesion. We have accounted for this in part by including a paired control of noncancerous breast tissue for each breast specimen. Further studies will be necessary to ascertain what enzymic defects or alterations may account for the excess PG tissue content characteristic of breast cancers.
Our preliminary results show that adjusted TXA2 production correlated with tumour size, axillary lymph node metastases and distant metastasis, sometimes with a concomitant decrease in PGI2. Honn et al. (1980 Honn et al. ( , 1981 Honn et al. ( , 1983 have proposed that the intravascular balance between PGI2 and TXA2 is disrupted in favor of platelet aggregation during development of tumour cell metastasis from Lewis lung carcinoma and B16 melanoma in mice. Such a shift in balance of TXA2/PGI2 in favor of TXA2 was also found to favour metastasis in two metastatic variants of a murine fibrosarcoma (Donati et al., 1982) . These findings in experimental studies support our preliminary results and suggest that tumour TXB2, PGI2 and PGE2 may be of value as tests for prognostic factors in breast cancer.
